Use of nonsteroidal anti-inflammatory drugs that elevate cardiovascular risk

The Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION) trial will evaluate the cardiovascular safety of celecoxib, ibuprofen, and naproxen. Approximately 20,000 patients with symptomatic osteoarthritis or rheumatoid arthritis at high risk for, or with, established cardiovascular disease will be randomized in this double-blind, triple dummy, multinational, multicenter study. The primary end point is the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The trial will continue until 762 primary events occur with at least 18 months follow-up. Noninferiority of any of the regimens will require a % upper CI of the hazard ratio (HR) < or = and point estimate < or = for both intent-to-treat (ITT) and modified ITT populations.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

Use of nonsteroidal anti-inflammatory drugs that elevate cardiovascular risk

use of nonsteroidal anti-inflammatory drugs that elevate cardiovascular risk

Media:

use of nonsteroidal anti-inflammatory drugs that elevate cardiovascular riskuse of nonsteroidal anti-inflammatory drugs that elevate cardiovascular riskuse of nonsteroidal anti-inflammatory drugs that elevate cardiovascular riskuse of nonsteroidal anti-inflammatory drugs that elevate cardiovascular riskuse of nonsteroidal anti-inflammatory drugs that elevate cardiovascular risk

http://buy-steroids.org